International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 14 Issue 2, April-June, Pages:29-34

A Comparative Study of Methotrexate Alone and Methotrexate with Hydroxychloroquine in Rheumatoid Arthritis Patients in A Tertiary Care Teaching Hospital

Dr. Pooja Agrawal, Dr. Virendra Kushwaha, Dr. Vipul Shukla , Dr. Praganesh Kumar, Dr. Amit Kumar, and Dr. Himanshu Sharma

Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease associated with polyarthritis and dysfunction of joints. Early diagnosis and treatment may affect disease outcomes even to a remission state. If not treated properly, it may increase morbidity and mortality due to extra-articular manifestations. No clear guidelines are available regarding the use of various Disease Modifying Anti Rheumatic Drugs and other immunosuppressive drugs in RA. Physicians have also used hydroxychloroquine (HCQS) due to its anti-inflammatory property. We aim to compare the effectiveness and safety profile of Methotrexate (MTX) monotherapy and HCQS in RA patients. Patients of RA attending Orthopaedic OPD at GSVM Medical College, Kanpur, are included and followed up for 6 months. Patients of Group A are treated with MTX alone, while Group B is treated with a combination of MTX plus HCQS. The effectiveness of the treatment is evaluated by improvement in the DAS28 scale at each follow-up visit. Drug safety profiles are assessed by Adverse drug reactions reported by patients and their causality assessment per Naranjo's probability score. In our study, 61 patients are included. The mean age is 49 years, while male to female ratio is 1:5. Improvement in the DAS28 score in the combination therapy group is significant (p value<0.05). Both groups had adverse events associated with their treatment. Still, none of the Adverse Drug Reactions was definite as per Naranjo's probability score, and a maximum number of Adverse Drug Reactions were non-serious. Our study concluded that combination therapy (MTX plus HCQS) provides better disease control. Combination therapy shows an almost similar safety profile; the frequency of adverse events was also similar to MTX alone. HCQS is a cost-effective drug easily available in India, so it would be better to use combination therapy in RA to control the disease.

Keywords: RA, MTX, HCQS, DAS28
Full HTML:
  1. Harris ED. Clinical features of rheumatoid arthritis. Kelley’s textbook of rheumatology. 7th ed. Amsterdam: Saunders Elsevier; 2005.
  2. Gibofsky A. Overview of Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13);Suppl:S295-302. PMID 23327517.
  3. Mijiyawa M. Epidemiology and semiology of rheumatoid arthritis in third world countries. Rev Rhum Engl Ed. 1995;62(2):121-6. PMID 7600065.
  4. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13(4):131-4. doi: 10.1007/BF00301258, PMID 8310203.
  5. Mota LM, Cruz BA, Brenol CV, Pereira IA, Fronza LS, Bertolo MB, et al. The consensus of the Brazilian society of rheumatology for diagnosis and early assessment of rheumatoid arthritis. Rev Bras Reumatol. 2011;51:207-19.
  6. Brazier Y. What is RA? Symptoms, treatments, causes, and everything you need to know [Internet]; updated 2021 Nov 11. Articles [cited May 25, 2022]. Available from:
  7. Lovering C. Four stages and progression of Rheumatoid arthritis (Internet) updated 2021Jan29 [cited May 25, 2022]. Available from:
  8. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for assessing joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968;37(147):393-406. PMID 4877784.
  9. Shah A, William E. Rheumatoid arthritis. In: Jameson et al., editors. Harrisons Principals of internal medicine2011;2743-50. 18th ed.
  10. Maddison PJ. Overlap syndromes and mixed connective tissue disease. Curr Opin Rheumatol. 1991;3(6):995-1000. doi: 10.1097/00002281-199112000-00016, PMID 1772755.
  11. Van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58(8):2241-7. doi: 10.1002/art.23681, PMID 18668546.
  12. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(2):118-23. doi: 10.1097/BOR.0b013e3283235ac4, PMID 19339921.
  13. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al. EULAR recommendations for managing rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573, PMID 24161836.
  14. Sing JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2015;126:2016;68.
  15. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. doi: 10.1038/s41584-020-0372-x, PMID 32034323.
  16. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
  17. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16?weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489, PMID 25359382.
  18. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev. 2016;2016(8): CD010227. doi: 10.1002/14651858.CD010227.pub2, PMID 27571502.
  19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi: 10.1002/art.27584, PMID 20872595.
  20. Kumar BS, Suneetha P, Mohan A, Kumar DP, Sarma KVS. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation. Indian J Med Res. 2017;146;Suppl:S57-62. doi: 10.4103/ijmr.IJMR_701_15, PMID 29578196.
  21. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989;32(5):531-7. doi: 10.1002/anr.1780320504, PMID 2719728.
  22. Kaur A, Dutta SB, Singh A, Varma A, Beg MA, Vishal SV. Comparative evaluation of efficacy and safety of methotrexate alone or in combination with hydroxychloroquine in patients who have rheumatoid arthritis. Int J Basic Clin Pharmacol. 2017;6(8):1996-2000. doi: 10.18203/2319-2003.ijbcp20173285.
  23. Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: an observational study. Indian J Pharmacol. 2016;48(5):591-4. doi: 10.4103/0253-7613.190761, PMID 27721549.
  24. Venkateswaran M, Dhanasekaran M, Rajavelu S. Prescribing pattern and adverse drug effects monitoring of anti-rheumatoid drugs in rheumatoid arthritis patients in a tertiary care hospital. Int J Basic Clin Pharmacol. 2019;8(3):1-7.
  25. Zhang L, Chen F, Geng S, Wang X, Gu L, Lang Y et al. Methotrexate (MTX) Plus hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-year Cohort Study in Real World. J Inflamm Res. 2020;13:1141-50. doi: 10.2147/JIR.S282249, PMID 33376379.
  26. Ma SN, Zaman Huri HZ, Yahya F. Drug-related problems in patients with rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:505-24. doi: 10.2147/TCRM.S194921, PMID 30962689.
  27. Fakhouri W, Lopez-Romero P, Antonelli S, Losi S, Rogai V, Buda S, et al. Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. Open Access Rheumatol. 2018;10:103-11. doi: 10.2147/OARRR.S164738, PMID 30127649.
  28. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727-34. doi: 10.1155/2013/726598, PMID 24324289.
  29. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines the structural progression of rheumatoid arthritis, dependent and independent of disease activity. Ann Rheum Dis. 2013 Jun;72(6):875-80. doi: 10.1136/annrheumdis-2012-201517, PMID 22798565.
  30. Palathingal TJM, Divya P, Govardhan SV. Interpret the safety and efficacy of hydroxychloroquine alone and methotrexate combination in rheumatoid arthritis. Int J Biomed Sci IJBS. 2020;16:1-4.
  31. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65(8):1985-94. doi: 10.1002/art.38012, PMID 23686414.
[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions